Dabrafenib CAS: 1195765-45-7
| Product Parameters | |
|---|---|
| Catalog No. | BA6Q63 |
| CAS.RN | 1195765-45-7 |
| Molecular Formula | C23H20F3N5O2S2 |
| Molecular Weight | 519.6 g/mol |
| Purity | NLT 98% |
Product Overview
Dabrafenib is a highly selective BRAF kinase inhibitor widely used in targeted cancer therapy, particularly for melanoma and other malignant tumors with BRAF V600 mutations. As an active pharmaceutical ingredient (API), dabrafenib is suitable for all stages of drug development, process development, and large-scale production, meeting the needs of various applications from laboratory trials to industrial pilot-scale and scale-up production. It is an important starting material for pharmaceutical companies in innovative drug development and formulation optimization.
Applications
- Synthesis of tumor-targeted therapy drugs
- Research on BRAF V600 mutation-related cancers
- Development and optimization of anticancer drug processes
- Custom synthesis of innovative drug intermediates
- Procurement and supply of active pharmaceutical ingredients (APIs) for pharmaceutical companies
Quality & Supply Capability
English Name: Dabrafenib Properties: White to off-white crystalline powder with good thermal and chemical stability. Contains a phenylpiperazine structure, readily soluble in organic solvents, and suitable for various synthetic routes. Storage Recommendations: Store in a sealed, light-protected, and dry place, referring to the COA/MSDS for specific details. Supply Capabilities: Samples, gram-level, kilogram-level, commercial batches. Packaging Specifications: Aluminum foil bags, fluorinated bottles, cardboard drums, customized packaging. Document Support: COA, MSDS, HPLC, NMR, etc. We provide a full-process service from sample supply, small-scale preparation, pilot-scale amplification to customized batch production. We can flexibly formulate supply solutions according to customers' specific requirements for purity, impurity control, packaging specifications, delivery cycle, and quality documentation. Simultaneously, we have a professional technical team to provide customers with comprehensive technical support from laboratory research and development to scale-up production, helping customers complete process development, route optimization, and project transformation, ensuring an efficient, compliant, and stable supply of active pharmaceutical ingredients.
Why Choose Bioncan
Focused on pharmaceutical raw materials, with extensive experience in supplying BRAF inhibitors. Full-scale supply capabilities, covering all stages from laboratory to commercial production. Provides complete quality control documentation to ensure product quality meets international standards. Supports customized needs, flexibly addressing different customers' purity, packaging, and delivery requirements. Provides process optimization and scale-up technical support to enhance customers' R&D efficiency and production conversion capabilities.
Intermediates of Dabrafenib
| Catalog No. | Product Name | CAS |
|---|---|---|
| BA6Q63 | Dabrafenib API | 1195765-45-7 |
| BK77DN | Dabrafenib Mesylate | 1195768-06-9 |
| BK422U | 2,2,2-Trimethylthioacetamide | 630-22-8 |
| BK38X9 | Methyl 3-(2,6-difluorophenylsulfonamido)-2-fluorobenzoate | 1195768-19-4 |
| BK62J0 | N-{3-[(2-chloro-4-pyrimidinyl)acetyl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide | 1195768-20-7 |
| BK2G78 | N-[3-[2-Tert-butyl-5-(2-chloropyrimidin-4-yl)-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide | 1195768-23-0 |
Customers are responsible for ensuring compliance with applicable patent, regulatory, and import/export requirements in their respective jurisdictions.
Online Consulting
For quotation, inventory, samples, COA, MSDS, or custom synthesis support for CAS 1195765-45-7, please submit your requirements. We will respond according to purity, quantity, delivery timeline, and documentation needs.
